These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 24041134)

  • 1. A novel noninvasive index for nonalcoholic steatohepatitis: a pilot study.
    Polyzos SA; Kountouras J; Slavakis A; Zafeiriadou E; Patsiaoura K; Katsiki E; Zavos C; Papatheodorou A; Terpos E
    Biomarkers; 2013 Nov; 18(7):607-13. PubMed ID: 24041134
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Noninvasive clinical model for the diagnosis of nonalcoholic steatohepatitis in overweight and morbidly obese patients undergoing bariatric surgery.
    Pirvulescu I; Gheorghe L; Csiki I; Becheanu G; Dumbravă M; Fica S; Martin S; Sarbu A; Gheorghe C; Diculescu M; Copăescu C
    Chirurgia (Bucur); 2012; 107(6):772-9. PubMed ID: 23294957
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical model for distinguishing nonalcoholic steatohepatitis from simple steatosis in patients with nonalcoholic fatty liver disease.
    Palekar NA; Naus R; Larson SP; Ward J; Harrison SA
    Liver Int; 2006 Mar; 26(2):151-6. PubMed ID: 16448452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum levels of hyaluronic acid and tissue metalloproteinase inhibitor-1 combined with age predict the presence of nonalcoholic steatohepatitis in a pilot cohort of subjects with nonalcoholic fatty liver disease.
    Miele L; Forgione A; La Torre G; Vero V; Cefalo C; Racco S; Vellone VG; Vecchio FM; Gasbarrini G; Rapaccini GL; Neuman MG; Grieco A
    Transl Res; 2009 Oct; 154(4):194-201. PubMed ID: 19766963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical and histological features of non-alcoholic fatty liver disease].
    Shi JP; Xun YH; Hu CB; Zhang L; Liu H; Lou GQ; Fan JG
    Zhonghua Gan Zang Bing Za Zhi; 2009 Nov; 17(11):812-6. PubMed ID: 19958638
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alcoholic liver disease/nonalcoholic fatty liver disease index: distinguishing alcoholic from nonalcoholic fatty liver disease.
    Cerović I; Mladenović D; Ješić R; Naumović T; Branković M; Vučević D; Aleksić V; Radosavljević T
    Eur J Gastroenterol Hepatol; 2013 Aug; 25(8):899-904. PubMed ID: 23426271
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Usefulness of a combined evaluation of the serum adiponectin level, HOMA-IR, and serum type IV collagen 7S level to predict the early stage of nonalcoholic steatohepatitis.
    Shimada M; Kawahara H; Ozaki K; Fukura M; Yano H; Tsuchishima M; Tsutsumi M; Takase S
    Am J Gastroenterol; 2007 Sep; 102(9):1931-8. PubMed ID: 17511754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive factors for nonalcoholic steatohepatitis (NASH) in patients with nonalcoholic fatty liver disease (NAFLD).
    Fierbinteanu-Braticevici C; Baicus C; Tribus L; Papacocea R
    J Gastrointestin Liver Dis; 2011 Jun; 20(2):153-9. PubMed ID: 21725512
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Helicobacter pylori eradication on hepatic steatosis, NAFLD fibrosis score and HSENSI in patients with nonalcoholic steatohepatitis: a MR imaging-based pilot open-label study.
    Polyzos SA; Nikolopoulos P; Stogianni A; Romiopoulos I; Katsinelos P; Kountouras J
    Arq Gastroenterol; 2014; 51(3):261-8. PubMed ID: 25296089
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its tumour necrosis factor-α-lowering property.
    Hyogo H; Yamagishi S; Maeda S; Kimura Y; Ishitobi T; Chayama K
    Dig Liver Dis; 2012 Jun; 44(6):492-6. PubMed ID: 22265683
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The ratio of aspartate aminotransferase to alanine aminotransferase: potential value in differentiating nonalcoholic steatohepatitis from alcoholic liver disease.
    Sorbi D; Boynton J; Lindor KD
    Am J Gastroenterol; 1999 Apr; 94(4):1018-22. PubMed ID: 10201476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serologic predictors of nonalcoholic steatohepatitis in a population undergoing bariatric surgery.
    Chisholm J; Seki Y; Toouli J; Stahl J; Collins J; Kow L
    Surg Obes Relat Dis; 2012; 8(4):416-22. PubMed ID: 21865094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum intercellular adhesion molecule-1 in patients with nonalcoholic steatohepatitis: comparison with alcoholic hepatitis.
    Ito S; Yukawa T; Uetake S; Yamauchi M
    Alcohol Clin Exp Res; 2007 Jan; 31(1 Suppl):S83-7. PubMed ID: 17331172
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Relationship between morphological diagnosis of NASH (non-alcoholic steatohepatitis) and liver function tests in a group of patients with morbid obesity].
    Chavarría-Arciniega S; López-Alvarenga JC; Uribe-Uribe NO; Herrera-Hernández M; González-Barranco J
    Rev Invest Clin; 2005; 57(4):505-12. PubMed ID: 16315634
    [TBL] [Abstract][Full Text] [Related]  

  • 15. One-year intense nutritional counseling results in histological improvement in patients with non-alcoholic steatohepatitis: a pilot study.
    Huang MA; Greenson JK; Chao C; Anderson L; Peterman D; Jacobson J; Emick D; Lok AS; Conjeevaram HS
    Am J Gastroenterol; 2005 May; 100(5):1072-81. PubMed ID: 15842581
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum cytokeratin-18 fragment levels are useful biomarkers for nonalcoholic steatohepatitis in children.
    Feldstein AE; Alkhouri N; De Vito R; Alisi A; Lopez R; Nobili V
    Am J Gastroenterol; 2013 Sep; 108(9):1526-31. PubMed ID: 23752877
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum levels of osteoprotegerin in the spectrum of nonalcoholic fatty liver disease.
    Yilmaz Y; Yonal O; Kurt R; Oral AY; Eren F; Ozdogan O; Ari F; Celikel CA; Korkmaz S; Ulukaya E; Imeryuz N; Kalayci C; Avsar E
    Scand J Clin Lab Invest; 2010 Dec; 70(8):541-6. PubMed ID: 20942739
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neutrophil to lymphocyte ratio: a new marker for predicting steatohepatitis and fibrosis in patients with nonalcoholic fatty liver disease.
    Alkhouri N; Morris-Stiff G; Campbell C; Lopez R; Tamimi TA; Yerian L; Zein NN; Feldstein AE
    Liver Int; 2012 Feb; 32(2):297-302. PubMed ID: 22097893
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: A randomized placebo-controlled trial.
    Nelson A; Torres DM; Morgan AE; Fincke C; Harrison SA
    J Clin Gastroenterol; 2009; 43(10):990-4. PubMed ID: 19448566
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease.
    Wieckowska A; Zein NN; Yerian LM; Lopez AR; McCullough AJ; Feldstein AE
    Hepatology; 2006 Jul; 44(1):27-33. PubMed ID: 16799979
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.